Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China

• Published in: Infection and drug resistance 2019-04, p.763
• Main Authors: Wang, Jing, Pang, Yu, Jing, Wei, Chen, Wei, Guo, Ru, Han, Xiqin, Wu, Limin, Yang, Guangxu, Yang, Kunyun, Chen, Cong, Jiang, Lin, Cai, Chunkui, Dou, Zhi, Diao, Lijuan, Pan, Hongqiu, Wang, Jianyun, Du, Feifei, Xu, Tao, Wang, Lixia, LJ, Renzhong, Chu, Naihui
• Format: Article
• Language: English
• Subjects: Analysis; Antibacterial agents; Antitubercular agents; Care and treatment; Cycloserine; Drugs; Elderly; Elderly patients; Hyperuricemia; Medical research; Microbial drug resistance; Morbidity; Psychological symptoms; Tuberculosis
• ISSN: 1178-6973; 1178-6973
• DOI: 10.2l47/IDR.S194484

Background: Our aim was to assess whether the use of cycloserine (CS) would bring additional benefit for multidrug-resistant tuberculosis (MDR-TB) patients, and to estimate the incidence and associated risk factors of adverse drug reactions (ADRs) from CS. Patients and methods: In this study, we retrospectively reviewed the clinical outcomes and ADRs of MDR-TB patients treated with CS containing regimens between January 2012 and June 2015 in China. Results: A total of 623 MDR-TB cases enrolled in this study received regimens containing CS. Of these cases, in 411 of the patients 374 (66.0%) were "cured" and 37 (5.9%) "complete treatment" by the end of the study. The elderly, patients with prolonged previous exposure to and history of anti-TB drugs, and pre-existing co-morbidity were more likely to be associated with adverse outcomes of MDR-TB patients (P